Progress Report: David Nanus, MD
Investigator: David Nanus, MD–Professor of Medicine, Professor of Urology, Mark W. Pasmantier Professor of Hematology and Oncology in Medicine at Weill Cornell Medical College Circulating Tumor Cell Biomarker Discovery of Taxotere Response Docetaxel (Taxotere) chemotherapy is the standard first line treatment for patients with castrate resistant prostate cancer (CRPC). Data. Read More
Progress Report: Towia Libermann, Ph.D; Alan Rigby, Ph.D
Co-Investigator: Towia Libermann, PhD–Associate Professor, Medicine, Director, Genomics and Proteomics, Beth Israel Deaconess Medical Center, Harvard Medical School, Director, Dana Farber Cancer Institute Cancer Proteomics Core, Harvard Medical School Co-Investigator: Alan Rigby, PhD–Assistant Professor, Medicine, Director, Program in Drug Discovery and Target Validation, Beth Israel Deaconess Medical Center, Harvard Medical. Read More
Progress Report: Karen Knudsen, Ph.D; Adam Dicker, MD, Ph.D
Co-Investigator: Karen Knudsen, PhD–Associate Professor, Department of Cancer Biology and Urology at the Kimmel Cancer Center, Thomas Jefferson University Co-Investigator: Adam Dicker, MD, PhD–Professor, Chairman of Radiation Oncology, Director of Christine Baxter Research Laboratory for Experimental Cancer Therapies, Co-Director Radiation Research and Translational Biology Program at the Kimmel Cancer Center,. Read More
Progress Report: Shelton Earp, MD; Joseph Desimone, Ph.D
Co-Investigator: Shelton Earp, MD– Director and Lineberger Professor, Professor of Medicine and Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill Co-Investigator: Joseph DeSimone, PhD–Chancellor’s Eminent Professor of Chemistry, University of North Carolina-Chapel Hill, William R. Kenan, Jr. Distinguished Professor of Chemical Engineering, North Carolina State University Application of. Read More
Progress Report: Cory Abate-Shen, Ph.D
Investigator: Cory Abate-Shen, PhD–Professor of Urology and Pathology, Director of Research, Department of Urology, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Identification of Oncogenic Pathways Conserved from Mouse to Man Dr. Abate-Shen’s research goals are to identify new molecules that drive prostate cancer progression. Her approach to this. Read More
PCCTC
PCF-Department of Defense Prostate Cancer Clinical Trials Consortium (PCCTC) As part of its aggressive plan to fund and accelerate research—and to speed the results to patients worldwide—PCF has invested more than $45 million in a consortium of 13 leading cancer centers, featuring some of the world’s most respected prostate cancer clinical. Read More
Progress Reports
As part of the award agreement, investigators are expected to make routine progress reports. Members of PCF’s Science Department regularly meet with the award winners to check in on their research. Please check back for new reports as they will be posted as processed. 2009 Creativity Award Reports Cory Abate-Shen, PhD Shelton Earp,. Read More
A New Generation of Researchers Pioneers Life Saving Solutions
PCF's Young Investigator Program gives recent MDs and PhDs the opportunity to conduct breakthrough research at a critical point in their careers as professional scientists. For these researchers, the first 7 or so years following the conferral of the terminal degree is a precarious and uncertain time. Academic positions are in. Read More
Not Your Father’s Prostate Cancer
What do recent medical advances mean for men and their families today, and how is this different from the experience of their fathers and grandfathers before them? And what does the future hold? Read More